Ventricular Assist Devices (Pediatric)

Pick the device

Patient BSA

Grays a device whose printed minimum BSA is above the band. Not a device choice.

Tap the device (ISHLT 2021 Table 1)
DeviceTypeConfigurationFlowSizeSupport time (approval)
Paracorporeal pulsatile, pneumaticLVAD, RVAD, BiVAD0.6–8 L/min>2.2 kg (smallest patient)Bridge to transplant (US); also destination (Europe)
Paracorporeal pulsatile, pneumaticLVAD, RVAD, BiVAD0.6–8 L/min>2.2 kg (smallest patient)Bridge to transplant (US); also destination (Europe)
Intracorporeal continuous flowLVADup to 10 L/min≥1.2 m² (MOMENTUM trial inclusion, not a limit) Bridge to transplant, destination
Paracorporeal continuous flowLVAD, RVAD, BiVADup to 1.5 (PediMag), 10 (CentriMag) L/minPediMag <20 kg; CentriMag not studied <18 yPediMag LVAD 6 h (US), 30 d (Europe); CentriMag LVAD 30 d (US, Europe); RVAD 30 d
AdultIntravascular axialLVADup to 4.3 (CP), >5.5 (5.5) L/min>1.0 m² (CP), >1.5 m² (5.5) (advisory board) Adult device4 d (CP), 14 d (5.5)
Pulsatile, replaces both ventriclesBiventricularup to 7.5 (50 cc), 9.5 (70 cc) L/min50 cc >1.2–1.85 m², 70 cc ≥1.7 m²; needs room in the chestBridge to transplant (50 cc); also destination (70 cc)
Intracorporeal continuous flow; withdrawn July 2021LVAD2–10 L/min≥1.2 m²Bridge to transplant, destination

EXCOR, IKUS driver

IKUS driver: settings, usual values on the sheet
SettingUsualSource
Pump size10, 15, 25, 30, 50, 60 ml (stroke volume)FDA SSED
RateNo range printed; a palpable pulse at the set rate111522
Systolic pressure (ejection)LVAD 180–250 mmHg, RVAD 80–150 mmHg (averages)111522
Diastolic pressure (suction)−20 to −40 mmHg111522
% systole (time ejecting)>30% and <50%111522
Fill and eject (membrane)Fill >75%; eject 100%111522

Aim: full fill and full ejection every beat (ISHLT 2021).

MRI contraindicated with an EXCOR (FDA SSED).

Estimated cardiac index on the sheet

Pump rate × pump size / (BSA × 1,000), assuming complete fill and ejection 111522.

Compare ISHLT 2021: rate × pump volume is the maximum output; actual output is generally less and hard to estimate.

EXCOR: what the FDA documents say

Bridge to transplant for children with severe isolated LV or biventricular dysfunction. Contraindicated: unable to take systemic anticoagulation; more than moderate aortic regurgitation that cannot be repaired, or whose repair closes the aortic valve; use as a total artificial heart. Blood chamber and cannulae are transparent, to see deposits and the filling and emptying. Approval study cohorts: BSA <0.7 and 0.7–<1.5 m², weight 3–60 kg. Inpatient only in the US (ISHLT 2021).

Based on ACTION Learning Network bedside sheets (EXCOR one-page summary 111522; Berlin Heart Emergency Algorithms & Care Guide algorithms; CPR Emergency Algorithms & Care Guide 2026 CPR guide); full sheets at myactioneducation.org (sign-in). Education material, not guidelines: the instructions for use and the centre decide.

Configurations

Our diagrams, from the text of ISHLT 2021: which circulation each pump takes over; boxes, not anatomy. LVAD or BiVAD applies only to biventricular circulations; a total artificial heart replaces both ventricles.

All devices by size

Every device in ISHLT 2021 Table 1, temporary and durable
Temporary devices (ISHLT 2021 Table 1)
DeviceTypeConfigurationFlowSizeSupport time (approval)
RotaFlowParacorporeal continuous flowLVAD, RVAD, BiVADup to 10 L/minAll6 h (US); up to 30 d (Europe)
PediMag US pediatric indicationParacorporeal continuous flowLVAD, RVAD, BiVADup to 1.5 L/min<20 kgLVAD 6 h (US), 30 d (Europe); RVAD 30 d
CentriMagParacorporeal continuous flowLVAD, RVAD, BiVADup to 10 L/minNot studied <18 yLVAD 30 d (US, Europe); RVAD 30 d
TandemHeartParacorporeal continuous flowLVAD, RVAD, BiVADup to 5 L/min>1.3 m² Adult device6 h
Protek DuoParacorporeal continuous flowRVADup to 4.5 L/minNeeds a 29 F sheath Adult device6 h
Impella 2.5, CPIntravascular axialLVADup to 2.5 (2.5), 4.3 (CP) L/min>1.0 m² (advisory board) Adult device4 d
Impella 5.0, 5.5Intravascular axialLVADup to 5.0 (5.0), >5.5 (5.5) L/min>1.5 m² (advisory board) Adult device14 d
Impella RPIntravascular axialRVADup to 4.0 L/min>1.5 m² Adult device14 d
Durable devices and total artificial heart (ISHLT 2021 Table 1)
DeviceTypeConfigurationFlowSizeApproval
Berlin Heart EXCOR US pediatric indicationParacorporeal pulsatile, pneumaticLVAD, RVAD, BiVAD0.6–8 L/min>2.2 kg (smallest patient)Bridge to transplant (US); also destination (Europe)
HeartMate 3Intracorporeal continuous flowLVADup to 10 L/min≥1.2 m² (MOMENTUM trial inclusion, not a limit)Bridge to transplant, destination
HVADIntracorporeal continuous flow; withdrawn July 2021LVAD2–10 L/min≥1.2 m²Bridge to transplant, destination
SynCardia TAH 50 cc US pediatric indicationPulsatile, replaces both ventriclesBiventricularup to 7.5 L/min>1.2–1.85 m²; needs room in the chest Bridge to transplant
SynCardia TAH 70 ccPulsatile, replaces both ventriclesBiventricularup to 9.5 L/min≥1.7 m²; needs room in the chestBridge to transplant, destination
Jarvik 2015 (investigational)Intracorporeal axialNot printed0.5–3 L/minStudy cohort 8–30 kgNo approval; trial ongoing at the time of the table

Right heart failure and tamponade

Low LVAD flow with suspected RV failure: echo

Check LA and LV decompression, aortic valve opening, septum (keep it midline), RV size, TR, cannula position. In small children beware over-decompression and leftward septal shift (ACTION 2025).

ACTION-ARC 2023 definition

Biventricular circulation only. One hemodynamic and one imaging finding, more than 72 h after the operation, with no device malfunction or thrombus. Hemodynamic: right-sided or systemic venous pressure >14 mmHg for >24 h, or clinical high venous pressure (effusions, ascites, hepatomegaly) with poor LVAD preload (calculated output <50% of expected, not helped by pump changes). Imaging: more than moderate/severe TR, or more than moderately/severely reduced RV function (as printed). Or: ECMO for right-sided failure, or an RVAD, at any time. Medical-only cases count after 10 days (ACTION-ARC 2023). Adult early RV failure (ISHLT 2021): inotropes >14 d, inhaled NO >48 h or unplanned RVAD. Early elective RVAD is linked to better outcomes than late emergent support (ISHLT 2021).

Hemolysis, pump thrombus, stroke

Definitions (ACTION-ARC 2023; children with acquired or congenital heart disease and adults with CHD on VADs; not ECMO)
EventDefinitionAt the bedside (ISHLT 2021)
HemolysisAny of, on 2 consecutive draws: plasma free Hb >50 mg/dl; LDH >3× the centre’s upper limit, no other cause; moderate or more hemolysed cells on smearLDH is the most sensitive marker
Pump thrombusPump or part exchanged for thrombus Inspect an EXCOR chamber; rising LDH: heparin or bivalirudin first
StrokeOvert or covert neurological event; severity by change in PCPCNon-contrast head CT within 30 min

Anticoagulation: regimens in use and why they differ

Monitoring, and why children differ

Monitoring: heparin by aPTT or anti-Xa; LMWH by anti-Xa; warfarin by INR; bivalirudin by aPTT and dilute thrombin time. Start anticoagulation only once hemostasis is achieved. Neonatal procoagulant factors are about 50% of adult levels; antithrombin, protein C and protein S are lower and fibrinolysis is reduced, so heparin is hard to titrate and adult protocols do not transfer. Milrinone, nitroprusside and inhaled NO inhibit platelets; VerifyNow and PFA-100 are not validated in children, and TEG platelet mapping tracks dose less well than once thought. Fever, high CRP or fibrinogen may prompt a change in anticoagulation or steroids; small studies suggest steroids may lower stroke on EXCOR (ISHLT 2021). Lesion-by-lesion targets: Antithrombotic Therapy.

Why regimens differ, one example: in single-centre before-and-after EXCOR cohorts (2009–14, 27 children), moving from two antiplatelet drugs titrated to TEG/PlateletMapping (Edmonton guideline) to three antiplatelet drugs uptitrated to high weight-based targets, with low-dose steroids for inflammation, was associated with 84% fewer strokes (0.8 vs 4.9 per 1,000 days of support) and less bleeding (Rosenthal 2017).

When to implant

INTERMACS/PEDIMACS profiles (CCS/CPCA 2026 Table 2)
ProfileDescriptionSupportPediatric implants
1Critical cardiogenic shockImmediate MCS (temporary or durable)30.4%
2Progressive decline on inotropesOnce stabilized, consider a durable VAD55.4%
3Stable but inotrope-dependentDurable MCS, planned electively11.1%
4–7Increasingly stableMedical management2.4%
Children with acute heart failure (CCS/CPCA 2026, GRADE)
StrengthRecommendation
Strong, very low certaintyIn medically unresponsive acute HF (profile ≥2), implant a VAD before cardiogenic shock rather than wait for profile 1 (rec 8)
Conditional, very low certaintyTemporary MCS (centrifugal or percutaneous axial pump) over VA-ECMO, in centres with VAD programmes; lung disease may need ECMO first (rec 9)
Conditional, low certaintyLeft heart decompression within 24 h on VA-ECMO (rec 10)

VA-ECMO, for comparison: CCS/CPCA 2026 suggests temporary MCS over VA-ECMO in acute heart failure (rec 9 above).

Devices, settings, troubleshooting and timing for children; Adult values labelled Adult.

Key points

Sources and how this page was checked

Full text read

Education material (not guidelines)

ACTION (Advanced Cardiac Therapies Improving Outcomes Network) bedside sheets from myactioneducation.org (sign-in needed), read 10 November 2026. Code = the number printed at the foot of each sheet. They are teaching material from a pediatric network; their typical ranges state no population. Each device screen draws on that device’s sheets only, tags each item with its sheet code, and ends by naming them; a guideline that differs is shown beside the item. Tag “algorithms” = the Berlin Heart Emergency Algorithms & Care Guide, which prints no code. “ACTION algorithm” links go to the sheet finder page. Sheet titles are as printed; “one-page summary” is ACTION’s name for the series on its site, not printed on the sheets.

Record only

How it was checked

Not covered on this page

ACTION sheet finder